Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis

BACKGROUND: Additional real-world studies are needed to more fully elucidate the effectiveness of antifibrotic treatment in slowing the progression of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To compare mortality and hospitalization between Medicare beneficiaries with IPF who initiate antifib...

Descripción completa

Detalles Bibliográficos
Autores principales: Mooney, Joshua, Reddy, Sheila R, Chang, Eunice, Broder, Michael S, Gokhale, Sohum, Corral, Mitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390936/
https://www.ncbi.nlm.nih.gov/pubmed/34818092
http://dx.doi.org/10.18553/jmcp.2021.27.12.1724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390936/
https://www.ncbi.nlm.nih.gov/pubmed/34818092
http://dx.doi.org/10.18553/jmcp.2021.27.12.1724

Ejemplares similares